IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

IN8bio (INAB) published pivotal Phase 1 clinical data for INB-200, its gamma-delta T cell immunotherapy candidate, in The Journal of Clinical Oncology—a tier-one oncology publication. This peer-reviewed validation represents a significant milestone for early-stage biotech validating novel cell therapy mechanisms in a high-mortality indication (glioblastoma).

The reported efficacy signal is striking: median progression-free survival of 16.1 months versus the ~6.9-month historical benchmark, representing a 2.3× improvement. Critically, the trial showed no dose-limiting toxicities, suggesting the therapy maintains a favorable safety profile—a major hurdle for engineered cell therapies. JCO publication de-risks the clinical narrative and enhances credibility with investors, regulators, and clinical partnerships.

For INAB, this data may catalyze near-term catalysts: accelerated Phase 2 initiation, potential partnership interest from larger oncology players, and improved access to capital. Glioblastoma remains an ultra-high unmet need with limited standard-of-care advances, positioning differentiated mechanisms favorably for valuation expansion.

Sector implication: This reinforces the biotech sector's confidence in cell therapy platforms and immuno-oncology durability. However, single-arm Phase 1 data carries execution risk; confirmation in randomized trials remains essential before commercial viability. Favorable publication momentum typically sustains 6–12 month momentum for clinical-stage names.